India, Oct. 27 -- Longeveron Inc. (LGVN), a clinical-stage biotechnology company, said Monday that an updated analysis of its Phase 2b ELPIS II trial showed significantly fewer major adverse cardiac events with laromestrocel, meeting a prespecified secondary endpoint after the trial missed its primary endpoint.
Hypoplastic left heart syndrome (HLHS) is a rare birth defect involving an underdeveloped left ventricle, limiting the heart's ability to pump blood.
Laromestrocel is an investigational cell therapy derived from healthy adult donors' bone marrow.
The randomized, double-blind trial assigned 40 infants equally to a single injection of laromestrocel into heart muscle during Stage II palliative surgery or surgery alone. Patients were ...